- SciSparc Ltd. announced the **closing of an acquisition** on October 24, 2025, gaining a **controlling interest of approximately 75%** in Neurothera Labs Inc. (TSXV: NTLX), a publicly traded company.  **[1611746_0001213900-25-102348_ea026258401ex99-1_scisparc.htm:0]** 
- As part of the transaction, SciSparc transferred its **advanced clinical stage pharmaceutical portfolio** and its **51% equity stake in SciSparc Nutraceuticals Inc.** to Neurothera, with these assets valued at approximately **US$11.6 million**.  **[1611746_0001213900-25-102348_ea026258401ex99-1_scisparc.htm:0]** 
- Neurothera's total enterprise value was approximately **US$3.3 million**, including **US$1.0 million in cash**, and SciSparc committed an additional **CAD 1,000,000** (approximately US$716 thousand) in capital via a convertible note.  **[1611746_0001213900-25-102348_ea026258401ex99-1_scisparc.htm:0]** 
- Neurothera's common shares are anticipated to **resume trading on the TSXV** under the symbol "NTLX" around **October 24, 2025**.  **[1611746_0001213900-25-102348_ea026258401ex99-1_scisparc.htm:0]**

SciSparc completes acquisition of Neurothera Labs Inc. and transfers pharmaceutical portfolio

- SciSparc Ltd. announced the **closing of the sale of its majority-owned subsidiary, MitoCareX Bio Ltd., to N2OFF, Inc.** on **October 20, 2025**.  **[1611746_0001213900-25-102142_ea0262426-6k_scisparc.htm:0]** **[1611746_0001213900-25-102142_ea026242601ex99-1_scisparc.htm:0]** 
- As consideration for its portion of the sale, SciSparc received a **cash payment of $700,000** and **490,751 shares of N2OFF common stock**, representing **16.75% of N2OFF** on a fully-diluted basis.  **[1611746_0001213900-25-102142_ea0262426-6k_scisparc.htm:0]** 
- The collective sellers, including SciSparc, will hold **40% of N2OFF's fully diluted capital stock** and are entitled to **30% of N2OFF's financing proceeds (capped at $1.6 million)** for five years, plus **milestone-based issuances of up to 25% of N2OFF common stock**.  **[1611746_0001213900-25-102142_ea026242601ex99-1_scisparc.htm:0]**

SciSparc Announces Closing of MitoCareX Sale to N2OFF

- **SciSparc Ltd.** has completed the acquisition of a controlling interest in **Neurothera Labs Inc.** (formerly Miza III Ventures Inc.), a publicly traded company on the TSX Venture Exchange.  **[1611746_ebe75565cf8d41779aa3ed2d1de8fb1c_0]** 
- As part of the transaction, SciSparc transferred its **advanced clinical stage pharmaceutical portfolio** and an approximately **51% equity stake** in SciSparc Nutraceuticals Inc. to Neurothera, with these assets valued at approximately **US$11.6 million**.  **[1611746_ebe75565cf8d41779aa3ed2d1de8fb1c_0]** 
- Following the closing, SciSparc holds an approximate **75% controlling interest** in Neurothera, which could increase up to approximately **84%**.  **[1611746_ebe75565cf8d41779aa3ed2d1de8fb1c_0]** 
- SciSparc also committed **CAD 1,000,000** (approximately US$716 thousand) in capital to Neurothera through an unsecured convertible note.  **[1611746_ebe75565cf8d41779aa3ed2d1de8fb1c_1]** 
- Neurothera's common shares are anticipated to resume trading on the TSXV under the symbol **"NTLX"** around **October 24, 2025**.  **[1611746_ebe75565cf8d41779aa3ed2d1de8fb1c_0]**

SciSparc Closes Acquisition of Controlling Interest in Neurothera Labs Inc.

- SciSparc Ltd. (SPRC) entered into a definitive asset and share purchase agreement on **October 9, 2025**, to acquire a controlling interest in Miza III Ventures Inc. (TSXV: MIZA.P).  **[1611746_0001213900-25-099227_ea026136201ex99-2_scisparc.htm:0]** **[1611746_0001213900-25-099227_ea0261362-6k_scisparc.htm:1]** 
- Under the agreement, SciSparc will transfer its advanced clinical stage pharmaceutical portfolio and an approximately **51% equity stake in SciSparc Nutraceuticals Inc.** to Miza, with these assets valued at approximately **US$11.6 million**.  **[1611746_0001213900-25-099227_ea026136201ex99-2_scisparc.htm:0]** **[1611746_0001213900-25-099227_ea0261362-6k_scisparc.htm:1]** 
- Following the Proposed Transaction, SciSparc is expected to hold a **controlling interest in Miza, ranging from a minimum of 75% to a maximum of 84%**.  **[1611746_0001213900-25-099227_ea026136201ex99-2_scisparc.htm:0]** **[1611746_0001213900-25-099227_ea0261362-6k_scisparc.htm:1]** 
- SciSparc also intends to commit up to **CAD1,000,000 (approximately US$716 thousand)** in capital to Miza through an unsecured convertible note, bearing **7% interest per annum**.  **[1611746_0001213900-25-099227_ea026136201ex99-2_scisparc.htm:0]** **[1611746_0001213900-25-099227_ea0261362-6k_scisparc.htm:2]** 
- The Proposed Transaction is anticipated to be completed by **October 22, 2025**.  **[1611746_0001213900-25-099227_ea0261362-6k_scisparc.htm:1]** **[1611746_0001213900-25-099227_ea026136201ex99-2_scisparc.htm:1]**

SciSparc Enters Definitive Agreement for Miza III Ventures Acquisition

- On **October 9, 2025**, SciSparc Ltd. entered a definitive agreement to acquire a controlling interest in **Miza III Ventures Inc.**, a publicly traded company on the TSX Venture Exchange.  **[1611746_ebaae146ecf24c5ab846b68a1faeb734_0]** 
- SciSparc will transfer its advanced clinical stage pharmaceutical portfolio and its **approximately 51% equity stake in SciSparc Nutraceuticals Inc.** to Miza, with these assets valued at **approximately US$11.6 million**.  **[1611746_ebaae146ecf24c5ab846b68a1faeb734_0]** 
- Following the closing, SciSparc is expected to hold a **controlling interest in Miza, ranging from a minimum of approximately 75% to a maximum of approximately 84%**.  **[1611746_ebaae146ecf24c5ab846b68a1faeb734_0]** 
- SciSparc intends to commit **up to CAD1,000,000 (approximately US$716 thousand) in capital to Miza** via an unsecured convertible note.  **[1611746_ebaae146ecf24c5ab846b68a1faeb734_1]** **[1611746_ebaae146ecf24c5ab846b68a1faeb734_3]** 
- The Proposed Transaction is anticipated to close **on or around October 22, 2025**.  **[1611746_ebaae146ecf24c5ab846b68a1faeb734_2]**

SciSparc Enters Agreement for Controlling Interest in Miza III Ventures Inc.

- **N2OFF shareholders approved the acquisition of SciSparc's majority-owned subsidiary, MitoCareX Bio Ltd., on September 25, 2025**, which will result in MitoCareX becoming a **wholly-owned subsidiary of N2OFF**.  **[1611746_0001213900-25-093386_ea025944701ex99-1_scisparc.htm:0]** 
- Under the agreement, N2OFF will purchase **6,622 shares of MitoCareX from SciSparc for $700,000** and exchange the remaining shares with all Sellers for N2OFF common stock, totaling **40% of N2OFF's fully diluted capital stock**.  **[1611746_0001213900-25-093386_ea025944701ex99-1_scisparc.htm:0]** 
- The Sellers are also entitled to **30% of N2OFF's financing proceeds (capped at $1.6 million) for five years** and **milestone-based issuances of up to 25% of N2OFF common stock**.  **[1611746_0001213900-25-093386_ea025944701ex99-1_scisparc.htm:0]** 
- The transaction is targeted to close in the **first half of October 2025**, subject to remaining closing conditions, and includes an **initial cash investment of $1,000,000** by N2OFF to support MitoCareX's operations for the first two years.  **[1611746_0001213900-25-093386_ea025944701ex99-1_scisparc.htm:0]**

SciSparc: N2OFF Shareholders Approve Merger with MitoCareX

- **N2OFF stockholders approved the acquisition of SciSparc's majority-owned subsidiary, MitoCareX Bio Ltd., on September 25, 2025**, clearing the path for MitoCareX to become a wholly-owned subsidiary of N2OFF.  **[1611746_da4d9771e9424c47b06d41244163c07c_0]** 
- Under the agreement, SciSparc will sell **6,622 shares of MitoCareX for $700,000**, and the sellers will collectively receive N2OFF common stock totaling **40% of N2OFF's fully diluted capital stock**.  **[1611746_da4d9771e9424c47b06d41244163c07c_0]** 
- The sellers are also entitled to **30% of N2OFF's financing proceeds (capped at $1.6 million)** for five years and potential milestone-based issuances of up to **25% of N2OFF common stock**.  **[1611746_da4d9771e9424c47b06d41244163c07c_0]** 
- N2OFF has committed to an initial **cash investment of $1,000,000** to support MitoCareX's operations for the first two years following the closing.  **[1611746_da4d9771e9424c47b06d41244163c07c_0]** 
- The transaction is aimed to close in the **first half of October 2025**, subject to the satisfaction of remaining closing conditions.  **[1611746_da4d9771e9424c47b06d41244163c07c_0]**

SciSparc: N2OFF Stockholders Approve MitoCareX Acquisition

- **SciSparc Ltd.** announced a new initiative to launch **quantum computing-enabled 3D protein modeling** to revolutionize AI drug discovery.  **[1611746_0001213900-25-091658_ea0258761-6k_scisparc.htm:0]** **[1611746_0001213900-25-091658_ea025876101ex99-1_scisparc.htm:0]** 
- This initiative aims to leverage quantum computing to achieve **unprecedented accuracy** in predicting protein structures and interactions, potentially accelerating drug discovery for neurological and rare diseases.  **[1611746_0001213900-25-091658_ea025876101ex99-1_scisparc.htm:0]** 
- The company plans to form a **dedicated research team**, collaborate with leading experts, and incorporate a **new wholly-owned Israeli subsidiary** to operate this initiative.  **[1611746_0001213900-25-091658_ea025876101ex99-1_scisparc.htm:0]** 
- Effective September 21, 2025, **Mr. Amitay Weiss was appointed President** and **Mr. Itschak Shrem was appointed Chairman of the Board**.  **[1611746_0001213900-25-091658_ea0258761-6k_scisparc.htm:0]**

SciSparc (SPRC)